HTA Council Final Recommendation on Reteplase (10 units lyophilized powder for IV injection) for ST-Elevation Myocardial Infarction Patients

The Secretary of Health (SOH) acknowledges the final recommendation of the HTA Council on reteplase (10 units lyophilized powder for IV injection) for ST-Elevation Myocardial Infarction (STEMI) patients  (date of receipt of acknowledgment: 02 January 2025). As a final recommendation, the HTA Council does not recommend the government financing of reteplase for STEMI patients. For continue reading : HTA Council Final Recommendation on Reteplase (10 units lyophilized powder for IV injection) for ST-Elevation Myocardial Infarction Patients

HTA Council Final Recommendation on Cerebrolysin [215.2 mg/ml, 10ml ampule for IV infusion] for the Treatment of adults with Post-Ischemic Stroke

The OIC-Secretary of Health (SOH) notes the final recommendation of the HTA Council on Cerebrolysin 215.2 mg/ml, 10ml ampule for IV infusion in combination with rehabilitation or standard of care for the treatment of adults with post-ischemic stroke (date of receipt of acknowledgment: 25 April 2023). As a final recommendation, the HTA Council does not continue reading : HTA Council Final Recommendation on Cerebrolysin [215.2 mg/ml, 10ml ampule for IV infusion] for the Treatment of adults with Post-Ischemic Stroke

HTA Council Final Recommendation on Ceftaroline fosamil (600 mg powder for concentrate for solution for injection) for the treatment of community-acquired pneumonia (CAP) in the pediatric population

The Secretary of Health (SOH) acknowledges the final recommendation of the HTA Council on ceftaroline fosamil (600 mg powder for concentrate for solution for injection) for the treatment of community-acquired pneumonia (CAP) in the pediatric population (date of receipt of acknowledgment: 13 January 2026). As a final recommendation, the HTA Council does not recommend the continue reading : HTA Council Final Recommendation on Ceftaroline fosamil (600 mg powder for concentrate for solution for injection) for the treatment of community-acquired pneumonia (CAP) in the pediatric population